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PackagingWepreviously described a single-cycle dengue vaccine (RepliVAXD2) engineered from a capsid (C) gene-deleted
West Nile virus (WNV) expressing dengue virus serotype 2 (DENV2) prM/E genes in place of the corresponding
WNV genes. Thatwork demonstrated that adaptation of RepliVAXD2 to grow inWNV C-expressing cells resulted
in acquisition of non-synonymous mutations in the DENV2 prM/E and WNV NS2A/NS3 genes. Here we demon-
strate that the prM/E mutations increase the speciﬁc infectivity of chimeric virions and the NS2A/NS3 mutations
independently enhance packaging. Studies with the NS2A mutant demonstrated that it was unable to produce a
larger form of NS1 (NS1'), suggesting that the mutation had been selected to eliminate a ribosomal frame-shift
“slippage site” in NS2A. Evaluation of a synonymous mutation at this slippage site conﬁrmed that genomes that
failed to make NS1' were packaged more efﬁciently thanWT genomes supporting a role for NS1/NS1' in orches-
trating virion assembly.gnostics, Inc., 45 Sidney Street,
ason).
rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Flaviviruses are single-stranded, positive-sense RNA viruses and
have an 11-kb genome with a single open reading frame encoding
three structural proteins (C, prM/M and E) and seven non-structural
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). Flavivirus
RNA replication occurs in the cell cytoplasm via a negative-strand
RNA intermediate, ultimately leading to the accumulation of
positive-strand RNAs. Several NS proteins have been implicated in ge-
nome replication. The NS2B/NS3 serine protease is required for pro-
teolytic processing at multiple sites in the viral polyprotein. NS3
also possesses RNA triphosphatase and RNA helicase activities and
NS5 contains methyltransferase and RNA-dependent RNA polymer-
ase activities (Lindenbach et al., 2007). NS1 is a non-structural glyco-
protein that is secreted from mammalian but not insect cells infected
by ﬂaviviruses (Mason, 1989), and is found at high concentrations in
the blood of viremic dengue patients (Alcon et al., 2002; Libraty et al.,
2002).NS1 is found in the viral polyprotein immediately following the
two structural proteins, prM/E. The coding regions of these proteins
are separated by signal peptidase cleavage sites, and all three proteins
acquire N-linked carbohydrates during their synthesis (Lindenbach
et al., 2007). prM and E form heterodimers which eventually undergo
a complicated maturation process that produces E dimers that cover
the surface of the mature viral particle (Li et al., 2008; Yu et al.,
2008). Early studies demonstrated that NS1 was slowly secreted
from mammalian cells, and studies with trans-expressed prM/E/NS1
cassettes suggested a role for NS1 in virion morphogenesis (Fan and
Mason, 1990; Konishi et al., 1991; Mason, 1989). However, work
with NS1 mutants demonstrated that NS1 played an essential role
in viral RNA replication (Muylaert et al., 1996; Muylaert et al., 1997).
The insect-vectored ﬂaviviruses are responsible for considerable
morbidity and mortality worldwide. The viruses exist on all conti-
nents of the world except Antarctica, and threaten much of the
world's population. DENV infections are estimated to occur in up to
100 million individuals annually and over 2.5 billion people live in
areas at risk for DENV infection. Vaccines are available for a number
of ﬂavivirus diseases, including YF and JE, but there are currently no
vaccines available for dengue. Among the marketed vaccines, the YF
vaccine, which consists of the live-attenuated strain YF-17D, has
been widely recommended to travelers, and has been considered to
be remarkably safe and efﬁcacious. However, recent documentation
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reconsideration of its safety and as a result, the American Committee
on Immunization Practices now recommends that the risk of infection
with YFV be taken into account when vaccinating travelers from non-
endemic regions (Staples et al., 2010). Nevertheless, YF-17D continues
to be an important public health tool, and has undisputable beneﬁt in
populations at high risk of YFV infection. In the case of JE vaccines, a
live-attenuated vaccine is widely used in China, but safety and
manufacturing issues have restricted it frombeing used in other regions
of theworld (Halstead and Thomas, 2011). In these areas, the product of
choice was an efﬁcacious inactivated mouse-brain derived virus, but
safety concerns prompted its removal from use. However, new prod-
ucts, including cell-culture derived inactivated vaccines and a chimeric
live-attenuated product based on YFV 17D are now being marketed in
developed economies (Halstead and Thomas, 2011).
Recently, we reported the development of single-cycle ﬂaviviruses
that can be used as safe and effective vaccines (Mason et al., 2006).
This single-cycle technology has been used to produce a series of vac-
cine candidates (named RepliVAX), that encode genomes harboring a
truncated C (trC) gene that prevents the RepliVAX genome from
being packaged into infectious particles unless the C gene is supplied
in trans (Ishikawa et al., 2008; Mason et al., 2006; Suzuki et al., 2009;
Widman et al., 2008). RepliVAX can infect normal cells in vaccinated
animals, and these infected cells release prM/E-containing sub-viral
particles (SVPs) and NS1 that induce effective antiviral immune re-
sponses. However, RepliVAX cannot spread or cause disease in ani-
mals, thus making them safe live-attenuated vaccines. The most
recent addition to the RepliVAX family is a chimeric RepliVAX that ex-
presses the prM/E genes of DENV2 in place of the WNV structural
genes, and this vaccine (RepliVAX D2) was able to control DENV2 dis-
ease in a mouse model for DENV2 infection (Suzuki et al., 2009).
During our development of RepliVAX D2, we discovered that the
initial construct grew poorly in C-expressing cells, but that growth
could be improved by extensive blind passage (facilitated by introduc-
tion of larger fragments of the C gene and passaging of packaging cells
along with the single-cycle virus). Analyses of these blind-passaged
variants demonstrated that their improved growth characteristics
were associated with the acquisition of speciﬁc mutations in the cod-
ing regions for prM, E, NS2A and NS3. In the case of the mutations in
prM and E, we used reverse genetics to show that a pair of mutations
in M (amino acid 9: G-NR and amino acid 13: E-NV; referred to by
convention as MR9G,V13E) and a single mutation in E (EK120T; number-
ing convention as shown forM) both operated individually to increase
yield of RepliVAX D2 in culture, but the combination of the M and E
mutations worked together to produce the greatest enhancement in
viral growth (Suzuki et al., 2009). Further, we showed that the muta-
tions in the NS2A (NS2AS9F) and the NS3 genes of the WNV backbone
(NS3R516K) enhanced growth of a re-engineered RepliVAX D2, but did
not appear to have an effect on genome replication per se, since they
were unable to enhance replication ofWNV replicons that did not con-
tain DENV genes (Suzuki et al., 2009).
Here we report that the mutations we identiﬁed in the growth-
adapted chimeric RepliVAX D2 constructs in the DENV2 prM and E re-
gion improve speciﬁc infectivity of ﬂavivirus particles in a manner
similar to that of a previously characterized heparan sulfate (HS)-
binding mutation at a nearby position in E (EK126E) (Lee et al.,
2006). In addition, we demonstrate that the mutation in the WNV
NS2A (which acts in concert with the WNV NS3 mutation) eliminates
the production of an altered form of NS1 (NS1') that arises from ribo-
some slippage at a site found inWNV, but not DENV (Firth and Atkins,
2009; Melian et al., 2010). Finally, we demonstrate that the elimina-
tion of the production of NS1' by introduction of a synonymous muta-
tion in this ribosomal slippage site improved encapsidation of
particles without altering the ampliﬁcation and translation of the ge-
nome, indicating a functional interaction between NS1/NS1' and the
structural proteins of ﬂaviviruses during encapsidation.Results
Mutations in DENV prM/E increase growth and alter speciﬁc infectivity
To determine how growth-enhancing mutations in the DENV2
prM/E coding region of single-cycle chimeric ﬂaviviruses expressing
the prM/E genes of DENV2 and the NS genes of WNV function (Suzuki
et al., 2009), we produced a series of packaging cell lines (see Fig. 1A)
that encoded the low passage DENV2 New Guinea C (NGC) prM/E se-
quences [BHK(VEErep/WNVC*-DENV2prM/E/Pac)] used to make our
ﬁrst generation RepliVAX D2 as well as a cell line [BHK(VEErep/
WNVC*-DENV2pr/MR9G,V13E/EK120T/Pac)] that encoded the DENV2
prM/E sequences selected when RepliVAX D2 was adapted to grow
in cells expressing the C gene (Suzuki et al., 2009). These packaging
cells, along with cell lines carrying packaging constructs expressing
the WNV prM/E [BHK(VEErep/WNVC*-E/Pac)], the JEV prM/E [BHK
(VEErep/WNVC*-JEVprM/E/Pac)], and a cell line [BHK(pVEErep/
WNVC*-DENV2prM/EK126E/Pac] expressing an E protein from a
high-passage NGC strain of DENV that contains a DENV2 E mutation
(EK126E) previously associated with HS binding (Lee et al., 2006)
(see Fig. 1A) were used to produce viral replicon particles (VRPs) con-
taining a WNV replicon (C-hFLuc2A-NS1-5, see Fig. 3A). When these
VRPs, which contained identical WNV-derived replicons transpack-
aged in the different coats provided by their packaging cell lines
(Fig. 1A), were tested side-by-side for their speciﬁc infectivities in
Vero cells (genome copies per IU; see Materials andmethods), we dis-
covered that theVRPs packaged inWNVor JEV prM/E proteins exhibited
signiﬁcantly better speciﬁc infectivities (500 to 2000 genome copies per
IU) than particles packaged in any of the DENV2 coats (50,000 to
200,000 genome copies per IU; Fig. 1B). Among the DENV2-packaged
VRPs, the VRPs coated with the prM/E proteins of a low-passage NGC
strain [from BHK(VEErep/WNVC*-DENV2prM/E/Pac)] displayed the
poorest infectivity (over 200,000 genome equivalents per IU), and the
particles packaged in coats containing the previously identiﬁed HS-
binding mutation at position 126 (Lee et al., 2006) [BHK(pVEErep/
WNVC*-DENV2prM/EK126E/Pac)] displayed a slightly better speciﬁc in-
fectivity. Interestingly, the VRPs packaged in the cell lines encoding
the DENV2 prM/E genes selected in our RepliVAX D2 passaging studies
(Suzuki et al., 2009) [BHK(VEErep/WNVC*-DENV2pr/MR9G,V13E/EK120T/
Pac)] displayed a signiﬁcantly better speciﬁc infectivity than the parti-
cles packaged in the WT DENV2-packaged VRPs, which contained
the same low-passage DENV2 genes used to initiate the passaging stud-
ies we performed with RepliVAX D2 (Suzuki et al., 2009) (Fig. 1B).
Taken together, these data demonstrate that the previously reported
low-speciﬁc infectivity of DENV particles (van der Schaar et al., 2007)
is due to the properties of the virion surface proteins and that changes
in speciﬁc infectivity in cell culture can be facilitated by addition of pos-
itively charged residues in M and E that presumably function by facili-
tating productive binding of negatively charged glycosaminoglycans
(GAGs) such as HS that are ubiquitously expressed on cells in culture
and aid in infection as previously demonstrated for DENV2 (Lee et al.,
2006). However, we cannot rule out the possibility that the mutations
in prM/E could also have a role in the maturation of the structural pro-
teins needed for ﬂavivirus morphogenesis, especially in light of recent
work showing that extracellular DENV particles contain a mixture of
mature (lacking prM) and immature particles (Junjhon et al., 2010)
which likely contribute to their poor speciﬁc infectivity.
NS2A and NS3 mutations previously selected in DENV2/WNV chimeras
improve VRP growth when packaged in DENV2 envelopes
During propagation of a derivative of RepliVAX D2 containing the
prM/E mutations described above (Suzuki et al., 2009), two muta-
tions were selected in the WNV nonstructural protein-encoding re-
gions that improved the growth of these chimeric viruses. To help
learn how these mutations exerted their effects, we introduced
Fig. 1. Effect of ﬂavivirus M/E proteins on the speciﬁc infectivity of trans-encapsidated WNV replicon genomes. (A) Schematic representation of the packaging cell constructs. All
constructs contained a form of the WNV C protein (C*) engineered to contain synonymous mutations in the start of the genome to prevent generation of homologous recombinants
with the replicons, as well as complete prM/E cassettes from the indicated viruses (see Materials and methods); “aa” indicates the position of the affected codon within the indi-
vidual protein-coding regions. (B). Speciﬁc infectivities of VRPs created by packaging aWNV-derived replicon [pWNR C-hFLuc2A NS1-5-encoding hFLuc (see Materials and methods
and Fig. 3A)]. Data displayed indicate the particle number (determined by genome quantiﬁcation using sqPCR) divided by the measured infectivity on Vero cells (see Materials and
methods). Error bars indicate the standard deviation between speciﬁc infectivity determinations established from twomeasurements of RNA concentration from the linear range of
the sqPCR standard curve. “*” denotes signiﬁcance as measured by one-way ANOVA with Bonferroni post-test (pb0.05).
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tested how these mutations affected the growth of this non-chimeric
single-cycle virus in a WNV C-expressing cell line [BHK(VEErep/
Pac-Ubi-C*)]. Fig. 2B shows growth curves for the WT and mutated
RepliVAX WN that were created by averaging values from 3 indepen-
dent experiments. These growth curves demonstrate that the muta-
tions selected in the context of the chimeric RepliVAX D2 were unable
to produce a detectable improvement in growth of the non-chimeric
RepliVAX WN.
To further evaluate the interactions between WNV NS2A and NS3
mutations and the DENV2 prM/E cassettes, NS2AS9F and NS3R516K
were introduced as single- or double-mutations into a WNV replicon
encoding a humanized form of the ﬁreﬂy luciferase (hFLuc) reporter
gene (Fig. 3A). Comparison of the ability of VRPs containing these repli-
cons to grow in a subset of the packaging cells described in Fig. 1 dem-
onstrated that each of the non-structural protein mutations enhanced
growth in all three of the DENV2 packaging cell lines (Figs. 3B, C
and D). In addition, the twomutations displayed an additive/synergistic
effect on transpackaging within DENV2 envelopes (Figs. 3B, C and D).
However, neither of these mutations (independently or together)
produced a detectable improvement in the growth of this WNV-
derived replicon when replicons carrying these mutations were
propagated in packaging cells expressing the WNV envelope pro-
tein cassette (Fig. 3E).NS2AS9F mutation alters the production of a higher molecular weight
form of NS1
The recent observation that the NS2A gene of encephalitic ﬂavi-
viruses contains a frame-shift motif (Firth and Atkins, 2009) that per-
mits the production of an altered form of NS1 [known as NS1'; (Melian
et al., 2010)] identiﬁed over 20 years ago in cells infected with JEV
(Mason, 1989) prompted us to further examine our NS2AS9F mutation.
Interestingly, this mutation disrupts the canonical UUUU portion of the
ribosome slip site that produces NS1' (CCCUUUU-NCCCUUcU; Fig. 4A).
To conﬁrm that this mutation prevented the synthesis of NS1', we con-
ducted Western blot analyses, that clearly demonstrate that this muta-
tion results in the loss of NS1' (Fig. 4B).Mutation of the ribosome slip site in NS2A enhances packaging of WN
replicons in DENV2 coats and eliminates production of NS1'
To demonstrate that the growth enhancing properties of the
NS2AS9F mutation resulted through the abrogation of NS1' production,
we engineered two silentmutations (CCCUUUU-NCCC cUUc) in this re-
gion of NS2A (producing a construct designated NS2AF9F) that dis-
rupted the ribosome slip site (Fig. 5A). WNV replicons bearing this
mutation alone, or in the presence of the NS3mutation, displayed a sig-
niﬁcant enhancement of growth compared to the WT replicon genome
when they were grown in cell lines providing DENV2 coats (Figs. 5B, C
and D). Furthermore, Fig. 5E shows that the NS2AF9F mutation, alone,
or in concert with the NS3R516K mutation produced a signiﬁcant im-
provement in packaging in a WNV coat at several time points. As
expected from the intentional disruption of the slippage site, cells
infected with replicons expressing the NS2AF9F mutation alone, or in
the presence of the NS3R516K mutation did not produce any detectable
NS1' (Fig. 5F). To further understand the interaction between the
NS2AF9Fand NS3R516K mutations and DENV coats, we investigated the
speciﬁc infectivity of C-hFLuc2A-NS1-5 and C-hFLuc2A-NS1-5 NS2AF9F
NS3R516K VRPs produced in the WNVC*-DENV2pr/MR9G,V13E/EK120T
and the WNVC*-E cell lines harvested from the 72 hpi time point in
the study shown in Figs. 5D and E. These studies showed improved in-
fectivity for the DENV-packaged VRPs that carried the NS2A frame-
shift and NS3 mutations relative to the WT genomes, but no difference
in the infectivity of the WNV-packaged genomes containing these mu-
tations (Figs. S2A and B), suggesting that the C-hFLuc2A-NS1-5 NS2AF9F
NS3R516K were more efﬁciently assembled into infectious DENV parti-
cles. Furthermore, Western blot analyses of the E protein content of
these same VRP preparations showed a similar level of incorporation
of WNV E into VRPs produced with either mutant or WT NS genes,
but a more efﬁcient incorporation of the DENV E into particles carrying
the mutant NS genes, consistent with the hypothesis that the NS2A
frame-shift and NS3 mutations produced higher infectious yields by in-
creasing efﬁciency of assembly of infectious particles with DENV coats.
To further evaluate the role of these mutations in virion packaging
in WNV coats, we utilized an additional, more sensitive assay consist-
ing of calculating the size of infectious foci formed by VRPs carrying
WT and mutant replicons on BHK(VEErep/WNVC*-E/Pac) cells.
Fig. 2. NS2AS9F and NS3R516K mutations do not signiﬁcantly improve the growth of RepliVAX derivatives carrying theWNV prM/E genes. (A) Schematic representation of derivatives
of RepliVAXWN carrying mutations in NS2A and NS3; “aa” indicates the position of the affected codon within the individual protein-coding regions. (B) Growth curves of the Repli-
VAXWN constructs shown in Fig. 2A on BHK(VEErep/Pac-Ubi-C*) which express the WNV C protein. Cells were infected at an MOI of 0.01, and media were harvested, and titered at
the indicated time points as described in the Materials and methods. The ﬁrst time point (0 hpi) indicates the initial dose used to infect the cells. Values represent averages of three
individual experiments. Error bars indicate standard deviation.
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Fig. 5E, by showing that all three VRPs tested in these assays tended
to produce larger foci on cells expressing the WNV structural proteins.
NS1 is required for ﬂavivirus genome replication, and mutations in
NS1 have been shown to alter genome replication in cells in culture
(see Introduction). To determine if the effect of NS1' abrogation was
producing the enhanced growth/spread phenotype in packaging cellFig. 3. NS2AS9F and NS3R516K improve growth of WNV VRPs when transpackaged in DENV co
NS2A and NS3; “aa” indicates the position of the affected codon within the individual protein
on BHK cell lines encoding the indicated packaging constructs. Cell monolayers were infected
indicated time points as described in the Materials and methods. The ﬁrst time point (0 hpi
dividual experiments. Error bars indicate standard deviation.lines, we infected WT BHK cells with VRPs harboring various repli-
cons and used the short-lived hFLuc reporter gene (Thompson et al.,
1991) to quantify the levels of their genome replication and polypro-
tein translation. These studies, shown in Fig. 7, showed that neither
the NS2AF9F, NS3R516K, nor the combined NS2AF9F/NS3R516K muta-
tions signiﬁcantly altered the levels of replicon ampliﬁcation at 24 h
post infection.ats. (A) Schematic representation of derivatives of WNV replicons carrying mutations in
-coding regions. (B–E) Growth curves of VRPs harboring the genomes shown in Fig. 3A
at anMOI of 0.05 with the indicated VRPs, and media were harvested and titered at the
) indicates the initial dose used to infect the cells. Values represent averages of two in-
Fig. 4. Effect of NS2AS9F mutation on synthesis of NS1'. (A) Alignment of RNA and amino acid sequences at the NS1/NS2A junction region of WNV showing the ribosomal frame-shift
site (underlined) and its disruption by the NS2AS9F mutation. (B) Western blot showing that cells infected with replicons encoding the NS2AS9F mutation fail to produce NS1'. Cells
infected with particles encoding C-hFLuc2A-NS1-5 replicon (labeled NS1-5 WT) and its derivatives (see Fig. 3A; labeled in this panel by mutation only) were lysed, blotted, and
immunostained as described in the Materials and methods.
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Flaviviruses display a broad host- and cell-speciﬁcity which sug-
gests that these viruses can use a variety of cell surface receptors.
Multiple molecules have been identiﬁed that can serve as receptors,
but the most clearly documented example of a cell-surface compo-
nent that can be utilized as a receptor is the GAG, HS. Although the
role of HS in natural infections by RNA viruses remains unclear, ﬂavi-
viruses that are adapted to grow in cell culture or in speciﬁc animalFig. 5. Demonstration that ablation of ribosomal frame-shifting in NS2A enhances trans-enc
and amino acid sequences at the NS1/NS2A junction region of WNV showing the ribosom
curves of VRPs harboring the WT replicon genomes, or genomes encoding the NS2AF9F or NS
Cell monolayers were infected at an MOI of 0.05 with the indicated VRPs, and media were
methods. The ﬁrst time point (0 hpi) indicates the initial dose used to infect the cells. Value
ation and “*” denotes signiﬁcance as measured by two-way ANOVA with Bonferroni post-tes
showed signiﬁcant differences in Fig. 5E; in this case: “*” denotes signiﬁcance (pb0.05)
(pb0.05) for C-hFLuc2A-NS1-5 NS2AF9F vs C-hFLuc2A-NS1-5NS2AF9FNS3R516K; and “***” de
cated timepoints. (F) Western blot showing that cells infected with VRPs containing the NS
NS1-5 replicons encoding NS3R516K, NS2AF9F, or NS2AF9F NS3R516K mutations were lysed, blmodels can acquire the ability to bind to HS through the acquisition
of mutations on the E protein that produce positively charged patches
that efﬁciently bind negatively charged GAGs (Anez et al., 2009;
Kroschewski et al., 2003; Lee et al., 2004; Lee and Lobigs, 2000; Lee
and Lobigs, 2002; Lee et al., 2006; Mandl et al., 2000). In the current
studies we used a transpackaging system to demonstrate that the
DENV2 M/E protein mutations found in our previously reported
cell-adapted dengue chimera (Suzuki et al., 2009) improve the specif-
ic infectivity of transpackaged particles, explaining the selection ofapsidation of WNV replicons and eliminates production of NS1'. (A) Alignment of RNA
al frame-shift site (underlined) and its disruption by silent mutations. (B–E) Growth
2AF9FNS3R516K mutations on BHK cell lines encoding the indicated packaging constructs.
harvested and titered at the indicated time points as described in the Materials and
s represent averages of two individual experiments. Error bars indicate standard devi-
t (pb0.05) for 24–96 h timepoints (B and C) and 48–72 h timepoints (D). The same test
for C-hFLuc2A-NS1-5 vs C-hFLuc2A-NS1-5NS2AF9FNS3R516K; “**” denotes signiﬁcance
notes signiﬁcance (pb0.05) for C-hFLuc2A-NS1-5 vs C-hFLuc2A-NS1-5 NS2AF9F at indi-
2AF9F mutation fail to produce NS1'. Cells infected with particles encoding C-hFLuc2A-
otted, and immunostained as described in the Materials and methods.
Fig. 6. Comparison of foci sizes of VRPs harboring the WT replicon genome, or genomes
encoding the NS2AF9F, NS2AF9FNS3R516K or NS3R516K mutations on BHK(VEErep/WNVC*-E/
Pac) cells expressing the WNV C-prM-E proteins. Cell monolayers were infected with serial
dilutions of the VRPs, overlaidwith semisolidmedium, ﬁxed, and immunostainedwith anti-
NS1 antibody 48 h after incubation at 37 °C as described in the Materials and methods. The
graph represents the counts of cells from 10 individual foci per VRP tested. The line repre-
sents the average of the 10 foci values for each group and “*” denotes signiﬁcance as mea-
sured by one-way ANOVA with Bonferroni post-test (pb0.001).
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in cell culture. Furthermore, by comparing the speciﬁc infectivity of
these preparations to those encoding envelopes of two encephalitic
ﬂaviviruses, we clearly demonstrated the poorer speciﬁc infectivity
of particles encapsidated in DENV envelope proteins, consistent
with work of Kuhn and co-workers documenting the poor speciﬁc in-
fectivity of DENV2 virions (van der Schaar et al., 2007). Interaction
among the proteins of positive-strand RNA viruses is one of the hall-
marks of these viruses. Among the ﬂaviviruses, numerous examples
of such interactions exist within the structural proteins or within
the well-deﬁned non-structural protein complexes. Analyses of viable
chimeras created from different species within the Flavivirus genus
have revealed additional interactions. Several of these have docu-
mented interactions between components known to be involved in
genome replication and the structural components of the virion.
Among these, there has been a documented interaction of NS1 with
the viral replicase via an interaction with NS4A (Lindenbach andFig. 7. Replication of VRPs harboring the WT replicon genome, or genomes encoding
the NS2AF9F, NS2AF9FNS3R516K or NS3R516K mutations on BHK cells. Cells were cultured
in 96-well plates, infected with VRPs and incubated for 24 h, when the relative lucifer-
ase units (RLU) were measured and then standardized to the number of VRP-infected
cells obtained by immunostaining wells infected in a parallel plate (see Materials and
methods). Data for each sample are averages of triplicate values with error bars show-
ing standard deviations.Rice, 1999). In a previous report we demonstrated that adaptation
of a DENV/WNV single-cycle chimeric ﬂavivirus to grow to higher ti-
ters in a speciﬁcally designed packaging cell line resulted in the selec-
tion of mutations in NS2A and NS3. Here we deﬁnitively demonstrate
that thesemutations exert their growth-enhancing effect by interaction
with the structural proteins, and that this growth enhancing effect is
more pronounced in the context of DENV2 structural proteins. These
data explain how these adaptations arose in response to the unnatural
chimerization. In the case of themutation in NS3,wewere unable to de-
ﬁne themechanism bywhich thismutationwas exerting its phenotype,
but the ability of this mutationwhich lies within the helicase domain of
NS3 to improve packaging of the viral genome supports previous evi-
dence showing that changes in the helicase domain can alter encapsida-
tion (Patkar and Kuhn, 2008).
In the case of our NS2A mutation, which was found at codon 9 of
the NS2A gene, we clearly demonstrate that this mutation functions
through alteration of a recently documented ribosomal frame shift
that produces an altered form of the NS1 protein (NS1') that is a char-
acteristic of members of the JEV/WNV serocomplex of the ﬂavivirus
genus (Firth and Atkins, 2009; Mason, 1989; Melian et al., 2010).
This interesting effect was evaluated by trans-complementation of
genomes carrying the cell-adapted, non-synonymous mutation in
NS2A which ablated the ribosome slippage site. These studies showed
that this non-synonymous change increased transpackaging by prM/E
proteins, and simultaneously eliminated the production of NS1'. The
speciﬁc role of the frame shift in these phenotypes was conﬁrmed
by studies which demonstrated that synonymous mutations in this
frame-shift site produced the same VRP growth-enhancing pheno-
type and ablation of NS1' production found in the non-synonymous
mutation selected in our previous blind-passaging studies. Careful an-
alyses of replicons harboring this mutation document that its effect
on genome packaging, which was additive with the NS3 mutation,
could be observed when packaging was evaluated in cells providing
WNV or DENV2 prM/E coats. However, the growth-enhancing pheno-
type was more dramatic with the DENV2 prM/E coats, consistent with
the hypothesis that these lower-speciﬁc infectivity coats provided a
more signiﬁcant selective pressure, allowing these mutations to
arise in the chimeric background used for the initial passaging stud-
ies; the selection of these mutations is also consistent with prelimi-
nary studies showing that the combination of the NS2A frame-shift
and NS3 point mutations into a replicon improve VRP yield from
DENV E-producing cell lines by improving the speciﬁc infectivity of
the resulting particles. Since the NS1 gene has been shown to serve
a critical function in ﬂavivirus genome replication we conducted
studies to determine if ablation of NS1' by alteration of the slippage
site could inﬂuence genome replication. These studies showed that
abrogation of NS1' had no effect on genome replication, indicating
that the mechanism by which NS1' alters particle packaging is due
to an effect on virion assembly/release.
Our data demonstrating that the NS1' protein alters genome pack-
aging expands the activities ascribed to the multifunctional NS1 pro-
tein. Although we have been unable to precisely determine how the
larger form of the NS1 protein interferes with transpackaging of ge-
nomes into infectious particles, these ﬁndings are consistent with
the slow egress of NS1 through the endoplasmatic reticulum (ER) of
infected mammalian cells (Mason, 1989), the regulation of its locali-
zation to several compartments (Youn et al., 2010), the documented
role of NS1 in genome replication (Muylaert et al., 1996; Muylaert
et al., 1997), and interactions with NS4A (Lindenbach and Rice,
1999), all of which indicate that NS1 likely serves as a bridge between
RNA synthesis and structural protein assembly. The ﬁnding that the
extended form of NS1 has an inhibitory effect on virion packaging in
vitro support this role. However, by themselves, these results are
somewhat surprising. The fact that the effect on packaging was less
pronounced in the presence of high-speciﬁc infectivity encephalitic
ﬂavivirus prM/E proteins is consistent with the fact that NS1' has
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by Khromykh and co-workers showed that abrogation of NS1' in a low-
virulence isolate ofWNV (Kunjin virus) reduced neurovirulence inmice
(Melian et al., 2010). Although these studies did not document an effect
of NS1' ablation on viral growth, they clearly showed an interesting ef-
fect of the NS1' protein in vivo but were unable to demonstrate any ef-
fect of the frame-shift ablation on growth of a mutant Kunjin virus in
vitro in mammalian or insect cells (Melian et al., 2010). The inability
to observe differences in growth of Kunjin viruses with or without the
frame-shift mutation is consistent with our studies showing that pro-
ductive growth of a single-cycleWNV (namely RepliVAXWN) in a com-
plementing cell line was not improved by the introduction of this
frame-shift mutation. Finally, although the inﬂuence of the frame shift
on Kunjin virus neurovirulencemaynot provide an evolutionary advan-
tage per se, the association of the frame-shift slippage site with the en-
cephalitic ﬂaviviruses likely reﬂects a selective biological advantage,
which could be related to acquisition of additional functions by the larg-
er form of NS1.
Materials and methods
Cells
BHK cells were maintained at 37 °C in minimal essential medium
(MEM) supplemented with 10% fetal bovine serum (FBS) and antibi-
otics. Vero cells were maintained at 37 °C in MEM containing 6% FBS
and antibiotics. BHK(VEErep/Pac-Ubi-C*) expressing theWNVCprotein
(Widman et al., 2008), BHK(VEErep/WNVC*-E/Pac) cells expressing the
WNV C-prM-E proteins (Fayzulin et al., 2006), BHK(VEErep/WNC*-
JEVprM-E/Pac) cells expressing the WNV C and JEV prM-E (Ishikawa
et al., 2008), BHK(VEErep/WNVC*-DENV2prM/E/Pac) cells expressing
theWNV C and the DENV2 NGC (low passage) prM/E (generated as de-
scribed below), BHK(VEErep/WNVC*-DENV2prM/EK126E/Pac) cells
expressing theWNV C and a HS-binding E derived from a high-passage
DENV2NGC (generated as described below), and BHK(VEErep/WNVC*-
DENV2pr/MR9G,V13E/EK120T/Pac) cells expressing the WNV C and the
DENV2 prM/E mutations selected in RepliVAX D2 (generated as de-
scribed below) were propagated at 37 °C in Dulbecco's MEM supple-
mented with 10% FBS and 10 μg/ml puromycin as previously
described (Fayzulin et al., 2006).
Plasmid construction
The plasmid pWNR C-hFLuc2A NS1-5 encoding a WNV replicon
expressing a hFLuc reporter gene has been previously described (Gilfoy
et al., 2009). This was used to construct the various mutant WNV repli-
con plasmidswith speciﬁcmutations in NS2A (pWNRC-hFLuc2ANS1-5
NS2AS9F), NS3 (pWNR C-hFLuc2A CNS1-5 NS3R516K), NS2A and NS3
(pWNR C-hFLuc2A NS1-5 NS2AS9F/NS3R516K), as well as a silent muta-
tion in NS2A (pWNR C-hFLuc2A NS1-5 NS2AF9F) using standard tech-
niques (Higuchi et al., 1988).
The plasmid encoding the RepliVAX WN replicon [pRepliVAX WN
(Widman et al., 2008); previously referred to as pRepliVAX WN.2 SP]
was modiﬁed using standard techniques to produce a series of mutant
RepliVAX WN plasmids with speciﬁc mutations in NS2A (pRepliVAX
WN NS2AS9F), NS3 (pRepliVAX WN NS3R516K), and NS2A and NS3
(pRepliVAX WN NS2AS9F/NS3R516K) using standard techniques
(Higuchi et al., 1988).
Plasmid pVEErep/WNVC*-E/Pac which encodes a Venezuelan
equine encephalitis virus replicon (VEErep) capable of persisting
in cells in the presence of puromycin and expressing the WNV struc-
tural proteins (C-prM-E) needed to package subgenomic replicons
(Fayzulin et al., 2006) was used to construct a series of plasmids encod-
ing a low-passageDENV2NGC (Fonseca, 1994) prM/E cassette (pVEErep/
WNVC*-DENV2prM/E/Pac), a high-passage DENV2 NGC (Fonseca, 1994)
prM/E cassette (pVEErep/WNVC*-DENV2prM/EK126E/Pac), or the prM/Ecassette found in cell-adapted RepliVAX D2 (Suzuki et al., 2009)
(pVEErep/WNVC*-DENV2pr/MR9G,V13E/EK120T/Pac). Sequences of all con-
structs are available from the authors upon request.
Production of packaging cell lines
Cell lines harboring replicons from the VEErep plasmids were cre-
ated by a slight modiﬁcation of the previously described procedures
(Fayzulin et al., 2006). Brieﬂy, the plasmid DNAs were linearized by
using the MluI restriction enzyme, and the resulting template DNAs
were in vitro-transcribed using MegaScript SP6 synthesis kit
(Ambion) in the presence of 7mG(ppp)G cap analog (New England
Biolabs). The yield and integrity of transcripts were determined by
using non-denaturing gel electrophoresis, aliquots of transcription re-
actions were transfected into BHK cells using Lipofectin (Invitrogen),
VEErep-harboring cell lines were selected in the presence of puromy-
cin, and clones displaying high-level expression of these replicons
were isolated and propagated using standard techniques.
Production of VRPs and RepliVAX WN derivatives
WNV replicon RNAs encoding the hFLuc gene (WNR C-hFLuc2A
NS1-5 and derivatives) or the WNV prM/E cassette (RepliVAX WN
and derivatives) were generated by using MegaScript T7 synthesis
kit (Ambion) and 7mG(ppp)G cap analog (New England Biolabs)
from SwaI-linearized templates created from the relevant plasmid
DNAs using standard methods. Following analysis for yield and integ-
rity as described above, aliquots of transcription reactions were elec-
troporated into packaging cell lines (expressing C, prM, and E
constructs in the case of the hFLuc-expressing replicon constructs or
C only in the case of RepliVAX constructs) and then collected as pre-
viously described (Fayzulin et al., 2006).
VRP and RepliVAX titrations
VRPs and RepliVAX WN derivatives were titrated on Vero cells as
previously described (Fayzulin et al., 2006). Yields are reported as in-
fectious units per milliliter (IU/ml).
VRP and RepliVAX growth curves
To compare growth properties of the various WNV replicons in
cell lines encoding various prM/E packaging constructs, VRPs derived
from electroporations were used to infect these BHK packaging cells
at a multiplicity of infection (MOI) of 0.05 for 2 h, the monolayers
were washed 3 times (5 min each) with MEM supplemented with
1% FBS, 10 mM HEPES, and antibiotics, and the cultures were placed
at 37 °C. Media were removed and replaced with fresh media at the
indicated time points and stored at −80 °C for subsequent titration
as described above.
Growth curves from RepliVAX WN and derivatives were prepared
by infecting BHK(VEErep/Pac-Ubi-C*) cells at an MOI of 0.01 using the
same procedure as described above.
Speciﬁc infectivity studies
Genome copy numbers and infectivity of VRPs produced by elec-
troporation (see above) were determined based on semiquantitative
PCR and Vero cell titration data. Brieﬂy, VRP preparations were dilut-
ed to give titers of 1000 IU/ml, and one portion was titered on Vero
cells as described above, while RNA was isolated from a second por-
tion using the QIAamp Viral RNA kit (QIAGEN) following the manu-
facturer's protocol. The viral RNA concentration in this sample was
determined by using a semiquantitative PCR (sqPCR) assay in which
serial 2-fold dilutions of RNA from each sample were used for reverse
transcription (RT) carried out with an ImProm II RT kit (Promega)
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product using previously described WNV NS5-speciﬁc primers
(Bourne et al., 2007). The PCR conditions included an initial cycle of
5 min at 95 °C, 30 cycles of 30 s at 95 °C, 30 s at 53 °C and 30 s at
72 °C, followed by 5 min at 72 °C. Following ampliﬁcation, the PCR
products were resolved by electrophoresis on 2% agarose gels con-
taining 200 ng/ml of ethidium bromide, and images of the gels were
acquired with a CCD camera using a FluorChem 8900 Chemilumines-
cence Gel Imager (Alpha Innotech) and band intensities were quanti-
ﬁed by using ImageJ software (available at http://rsbweb.nih.gov/ij/).
The intensities of these bands were compared to a standard curve
generated with known numbers of genome copies of in vitro synthe-
sized RNA from WNR C-hFLuc2A NS1-5 (ranging from 2000 to
200,000 copies), and the resulting standard curve (generated by
using GraphPad Prism 4 software) (Fig. S1) was used to calculate
the genome copies in each test sample. The speciﬁc infectivities of
each preparation were then calculated by dividing this genome copy
number per IU in the same sample volume, giving genome copies/IU
of each VRP.
Western blot analyses of NS1
VRPs containing different derivatives of WNR C-hFLuc2A NS1-5
were inoculated onto BHK cell monolayers at an MOI of 5 and incu-
bated at 37 °C with serum-free medium (OptiPro SFM, Gibco) supple-
mented with 10 mM HEPES and antibiotics. At 24 h after infection,
culture ﬂuids were collected and cell lysates were prepared using
lysis buffer (0.1% Triton X-100, 300 mM NaCl, 50 mM Tris–HCl; pH
7.6) containing a protease inhibitor cocktail (Roche). Samples were
resolved on 4–12% gradient Bis–Tris polyacrylamide gels (Invitrogen)
and transferred to polyvinyldene dioﬂuoride membranes, which were
then incubated with a 1:5000 dilution of a mouse anti-NS1 antibody
from hydridoma JE-6H4 (Kitai et al., 2007). Following washing, the
membranes were incubated with a 1:10,000 dilution of peroxidase-
conjugated anti-mouse IgG (KPL), and the bound peroxidase was vi-
sualized by using ECL Plus System (GE healthcare).
VRP focus-formation assay
To compare focus morphology, monolayers of BHK(VEErep/
WNVC*-E/Pac) cells expressing the WNV C-prM-E proteins were
infected with serial dilutions of VRPs harboring the WT replicon ge-
nome, or genomes encoding the NS2AF9F, NS2AF9FNS3R516K or
NS3R516K mutations. Following absorption for 2 h, the cells were over-
laid with medium containing 0.8% carboxymethyl cellulose (CMC)
(Sigma, Saint Louis, MO) supplemented with 1% FBS, 10 mM HEPES
and antibiotics and incubated at 37 °C for 48 h. To visualize foci, the
cells were ﬁxed with 50% acetone–50% methanol solution followed
by incubation with a 1:5000 dilution of a mouse anti-NS1 antibody
from hybridoma JE-6H4 (Kitai et al., 2007), peroxidase conjugated
anti-mouse IgG (KPL, Gaithersburg, MD) and VIP substrate (Vector
Laboratories, Burlingame, CA). The number of cells forming individu-
alized focus was counted and used to compare focus size.
Luciferase assay
BHK monolayers prepared in 96-well black-wall plates were
infected with dilutions of VRPs harboring the WT replicon genome,
or genomes encoding the NS2AF9F, NS2AF9FNS3R516K or NS3R516K mu-
tations and incubated at 37 °C. At 24 h post infection, an equal volume
of 25% Steady-Glo Luciferase Assay System reagent (Promega) diluted
in lysis buffer was added to the cells and incubated for 5 min on rock-
er to allow cell lysis. The luminescence was measured on a Microplate
Luminometer (Applied Biosystems, Foster City, CA). A parallel plate
infected with the same dilutions of VRPs was harvested at 24 h post
infection and used to determine the number of VRP-infected cellsdetermined by immunostaining (as described above). The luciferase
activity was normalized by the number of VRP-infected cells and
expressed as relative luciferase units (RLU) per infected cell.
Statistical analyses
GraphPad Prism (GraphPad Software, San Diego, CA) was used to
analyze data. One-way or two-way analysis of variance (ANOVA)
with the Bonferroni post-test were used where appropriate. P values
less than 0.05 were considered to indicate statistical signiﬁcance.
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